Esperion Therapeutics shares are trading higher after BofA Securities upgraded the stock to Buy from Underperform and raised the price target from $1.25 to $4.
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics' stock has been upgraded to Buy from Underperform by BofA Securities, with the price target raised from $1.25 to $4.
June 15, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics' stock upgraded to Buy from Underperform by BofA Securities, with a higher price target of $4.
The upgrade from BofA Securities to Buy from Underperform and the increase in the price target from $1.25 to $4 indicate a positive outlook for Esperion Therapeutics. This is likely to have a positive short-term impact on the stock price as investors may see this as a signal to buy the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100